Bolt Biotherapeutics, Inc.

Bolt Biotherapeutics, Inc. is a biotechnology company focused on developing product candidates that utilize the immune system to treat cancer. The company's pipeline candidates are based on its expertise in myeloid biology and cancer drug development. Bolt Biotherapeutics' approaches leverage pattern recognition receptors of the innate immune system to help the body eliminate tumor cells. The company's proprietary Boltbody™ Immune-Stimulating Antibody Conjugate, or ISAC, platform technology combines tumor-targeting antibodies with immune-stimulating linker-payloads. This platform aims to create products that work with a patient's immune system to achieve anti-cancer activity with acceptable tolerability. Bolt Biotherapeutics has explored over one thousand distinct linker-payloads and multiple tumor targets, developing a library of linker-payloads for its own development programs and collaborations. BDC-4182 is a next-generation Boltbody™ ISAC that targets the tumor-associated antigen claudin 18.2. Claudin 18.2 is a clinically validated oncology target, with zolbetuximab, a claudin 18.2-targeted monoclonal antibody, approved in Japan, the U.S., and other countries for treating claudin 18.2-positive, unresectable, advanced or recurrent gastric cancer in combination with chemotherapy. Other programs targeting claudin 18.2 are in development for gastric/gastroesophageal junction cancer, pancreatic cancer, and other tumor types. BDC-4182 has demonstrated potent anti-tumor activity in multiple preclinical models, safety and tolerability in toxicology studies, and enhanced anti-tumor activity compared to cytotoxic antibody-drug conjugates (ADCs) in murine tumor models. Data on the claudin 18.2 Boltbody ISAC program was presented at the Society for Immunotherapy of Cancer's (SITC) Annual Meetings in November 2025, 2024, and 2023. The first-in-human Phase 1 dose escalation trial of BDC-4182 is ongoing in subjects with gastric/gastroesophageal junction cancer.